相关实验视频
Updated: Jun 28, 2025

08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.2K
在患有无控高血压,有或没有损伤的患者中发现新的生物标志物
Karl Marius Brobak1,2, Lene V Halvorsen3,4,5, Hans Christian D Aass6
1Section of Nephrology, University Hospital of North Norway, Tromsø, Norway.
Blood pressure
|April 12, 2024
概括
新的生物标志物可能有助于比目前的方法更早地检测高血压介导器官损伤 (HMOD). 奥斯托邦丁 (OPN) 显示出在识别患有无控高血压,损伤风险的患者中的潜力.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 生物标志物发现发现
背景情况:
- 目前的eGFR和ACR等生物标志物对于早期检测高血压介导器官损伤 (HMOD) 是不够的.
- 识别新的生物标志物对于管理高血压和预防末端器官损伤至关重要.
研究的目的:
- 研究血生物标志物,以便在健康人和高血压患者中早期检测HMOD.
- 评估这些生物标志物是否可以区分高血压的严重程度,并预测损伤.
主要方法:
- 一项全国性的横截面研究,涉及176名高血压患者和39名健康对照.
- 使用Luminex免疫试验分析了15种潜在的生物标志物,重点是干白素1受体对抗剂 (IL-1RA),中性粒细胞凝酶相关性脂卡林 (NGAL),乌罗莫杜林,骨质 (OPN) 和RANTES.
- 高血压组被分为受控,不受控制,没有脏HMOD,不受控制的脏HMOD.
主要成果:
- 在健康对照组和高血压患者之间,血IL-1RA,NGAL和乌罗莫杜林水平显著不同.
- 奥斯托邦丁 (OPN) 与没有脏HMOD (OR 1.77) 的不受控制的高血压有关.
- 兰特斯与无控高血压与脏HMOD相关 (OR0.57),但在考虑已确定的风险因素时,没有生物标志物可靠地区分高血压组.
结论:
- 已经确立的生物标志物,如eGFR和ACR在早期检测HMOD时是有限的.
- 血骨质红素 (OPN) 可能作为一种潜在的生物标志物,用于识别患有脏HMOD风险的不受控制的高血压患者.
- 需要进一步的研究来验证这些发现,并探索它们在高血压管理中的临床实用性.
相关概念视频
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Antihypertensive Drugs: Direct Renin Inhibitors
613
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
613
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
627
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K

